← Leaderboards
Keli L Hippen
University Of Minnesota
$2,499,187
Attributed
$4,998,373
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $722.5K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,998,373 · 1
By mechanism
R01$4,998,373 · 1
Top collaborators
- Bruce R. Blazar8 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Bruce R. Blazar$144,460,093
- Jeffrey S Miller$32,066,338
- Brian T Fife$14,145,163
- John E Wagner$7,593,142
- Jakub Tolar$8,610,650
Others in their field
Other Emerging Leaders on “Metabolic”
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Barbara Halina Braffett · George Washington University$22,016,904
- Ionut Bebu · George Washington University$18,816,779
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$15,459,738
- Rainer Lohmann · University Of Rhode Island$14,400,221
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$14,236,023
Research focus
MetabolicPre-ClinicalImmune ResponseLoss Of FunctionNovel StrategiesPathway InteractionsDisease ModelHematopoietic Stem CellsImmunological SynapseInsightCellsMitochondriaAntigen-Presenting CellsOxidative PhosphorylationClinicAutoimmunityFirst-In-HumanGraft Vs Host DiseaseBiologicalImmune SystemInflammatoryInfusion ProceduresAffectPrevent
Grant awards (8)
Enhancing Treg Therapeutic Efficacy in GVHD$683,148
R01 · FY2025 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$671,440
R01 · FY2024 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$696,797
R01 · FY2023 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$722,503
R01 · FY2022 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$549,004
R01 · FY2021 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$549,402
R01 · FY2020 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$549,793
R01 · FY2019 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$576,286
R01 · FY2018 · HL